drugset / Trial / NCT01522651
Study to Evaluate the Effect of Ranolazine and Dronedarone When Given Alone and in Combination in Patients With Paroxysmal Atrial Fibrillation
RandomizedParallel-groupDouble-blindTreatment
Summary
The primary objective of this study is to evaluate the effect of ranolazine and of low-dose dronedarone when given alone and in combination at different dose levels on atrial fibrillation burden (AFB) over 12 weeks of treatment. AFB is defined as the total time a participant is in atrial tachycardia/atrial fibrillation (AT/AF) expressed as a percentage of total recording time.
Timeline
- Start
- 2012-01-24
- Primary completion
- 2014-03-10
- Completion
- 2014-03-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dronedarone | Small molecule | 150 mg | Oral |
| Subject | Dronedarone | Small molecule | 225 mg | Oral |
| Subject | Ranolazine | Small molecule | 750 mg | Oral |